Stock Financial Ratios

BIVV / Bioverativ Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)5,992.55
Enterprise Value ($M)5,768.45
Book Value ($M)0.00
Book Value / Share0.00
Price / Book7.99
NCAV ($M)0.00
NCAV / Share0.00
Price / NCAV5.22
Income Statement (mra) ($M)
Net Income0.00
Balance Sheet (mrq) ($M)
Cash & Equivalents224.10
Cash / Share0.00
Quick Ratio0.00
Current Ratio0.00
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.00
Identifiers and Descriptors
Central Index Key (CIK)1681689
Industry Groups
Share Statistics
Common Shares Outstanding (M)108.20
Scoring Models
Piotroski F Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Assets Other Non Current Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Liabilities Current Per Share0.00
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities Per Share0.00
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Cash Per Share0.00
Inventory Finished Goods Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Current Per Share0.00

Related News Stories

Tracking Jeffrey Ubben's ValueAct Portfolio - Q3 2017 Update

3h seekingalpha
The top three positions are Twenty First Century Fox, Alliance Data Systems, and Baker Hughes and they add up to ~38% of the portfolio. (288-0)

Sangamo's Powerful Pipeline Drives Significant Upside

2017-11-17 seekingalpha
While there has been a high level of excitement over the past few years with regard to CRISPR gene editing possibilities, some of the previously leading methods for effective genome manipulation and gene therapy have been lost in the mix. Sangamo Therapeutics (SGMO) has a strong proprietary product in their Zinc Finger Nuclease [ZFN] technology for genome modulation. They have recently generated significant buzz surrounding their widely successful quarter, and have laid a strong foundation moving forward. (52-0)

Biogen: Analysis Of Q3 And Recent Events

2017-10-25 seekingalpha
Caution on BIIB's dominant MS franchise's implied valuation makes me think that the stock is unattractive to new money investors at its current price above $300. (96-0)

Sangamo Therapeutics: The Breakthrough In Gene Therapy

2017-08-17 seekingalpha
SGMO is initiating its execution of commercially viable ZFN drugs, facilitating future pharmaceutical solutions and a financial instrument with which to hedge CRISPR.

Bioverativ: What A Pipeline

2017-08-07 seekingalpha
Bioverativ (BIVV) is the spunky spin-off from Biogen (BIIB) that could be incubating a blockbuster drug to treat hemophilia. Since this baby biotech was divested from Biogen in February, it has generated almost a billion in revenues. Earnings per share have risen 50 percent in 2017 to $4.09. Companies typically spin-off high-growth businesses to capture such shareholder value, which is often lost in a large conglomerate.

CUSIP: 09075E100